Shanghai exchange rebukes BrightGene for statements on remdesivir

BrightGene shares tumbled as the Shanghai exchange reprimanded the company for misstatements regarding its production of antiviral candidate remdesivir from Gilead.

In a statement Sunday, the exchange reported the results of its investigation into a Feb. 12 filing from BrightGene Bio-medical technology Co. Ltd. (Shanghai:688166) indicating the company was mass producing the API for remdesivir...